




I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: November 4, 2002

Signature: 
(Arnold H. Krumholz)

#42/E
mp
2/13/03

Docket No.: BERTEK 3.0-025
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Govil et al.

Application No.: 08/883,075

Group Art Unit: 1617

Filed: June 26, 1997

Examiner: E. [redacted]bman

For: ADHESIVE MIXTURE FOR TRANSDERMAL
DELIVERY OF HIGHLY PLASTICIZING
DRUGS

Commissioner for Patents
Washington, DC 20231

RECEIVED
FEB 03 2003
TECH CENTER 1600/2900

AMENDMENT

Dear Sir:

In response to the official action mailed July 23, 2002, in which claims 84 and 86-92 were rejected, applicants submit the following amendments and remarks.

IN THE SPECIFICATION

CLEAN COPY OF AMENDED SPECIFICATION PARAGRAPHS:

Amend the paragraph beginning on page 11, line 24, and ending on page 12, line 5, as follows:

Applicants have also discovered that the traditional bench-top methods of gauging the performance of such adhesives are unreliable with particularly highly plasticizing drugs like selegiline. Therefore while tests like shear strength, peel tests from a steel plate and tack tests may eliminate certain candidates, they will not reliably identify successful candidates. Instead, it was discovered that the acrylic polymeric adhesives that worked the best in these application all have similar compositions. Generally, they include a C₄-C₁₂

EI